Brian G. Coleman is the founder of Domino Analytics (http://www.dominoanalytics.com/) a free investment research site for serious independent investors focused on emerging growth stocks. Our members include professional and individual investors, as well as engineers, technologists, physicians, entrepreneurs, and corporate professionals. The common trait among our members is a passion for independent research and an ability to bring unique non-public insights to the investment process. Brian has 17 years of professional investment experience including eight years (1992-1999) as a sell-side research analyst with major Wall Street firms including Lehman Brothers and Alex. Brown and Sons, and nine years experience managing venture capital and hedge funds. In addition to managing Domino Analytics, Brian also manages Hawk Hill Asset Management which invests in both private and public emerging growth equities.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Brian G. Coleman is the founder of Domino Analytics (http://www.dominoanalytics.com/) a free investment research site for serious independent investors focused on emerging growth stocks. Our members include professional and individual investors, as well as engineers, technologists, physicians, entrepreneurs, and corporate professionals. The common trait among our members is a passion for independent research and an ability to bring unique non-public insights to the investment process.
Brian has 17 years of professional investment experience including eight years (1992-1999) as a sell-side research analyst with major Wall Street firms including Lehman Brothers and Alex. Brown and Sons, and nine years experience managing venture capital and hedge funds. In addition to managing Domino Analytics, Brian also manages Hawk Hill Asset Management which invests in both private and public emerging growth equities.
I am a professional investor with a specific interest in technology and biotechnology. A qualified attorney, I have been investing for thirty years. I am not an active trader. My preference is to identify quality emerging situations that fit a strict investment criteria, and from there build a long term position over a period of months or years. In essence, effective stock-picking.
I do not believe Value Investing need necessarily be limited to established companies in a temporarily undervalued situation. Many attractive opportunities exist with emerging companies which do not fit the strict criteria for traditional Graham model of value investing, yet offer significant capital growth potential for early investors willing to accept a higher risk position than normal.
In my experience this approach is well-suited to the Technology/Biotechnology sectors.
I am not a qualified financial advisor. Any opinions expressed on Seeking Alpha are my own and should not be relied upon in making your own personal investment decisions. As always, Do Your Own Research and if in doubt, ask the advice of a qualified financial advisor.
Individual investors should feel free to message me privately about my real-time subscription service, which is very affordable. That is also included with my short idea product for institutional investors, here on Seeking Alpha.
For a better mobile experience on Seeking Alpha click the top right menu icon on most browsers and select "request desktop site".
I am a former financial communications programmer, turned full-time investor. I began investing in the mid-1990s, looking for a way to achieve early retirement. (A goal in which I have succeeded, if you don't consider full-time investing a job.) I took a scientific, experiment-based approach rather than a studious one. I feel that this approach, combined with my extensive programming work in financial markets and directly with traders has given me uncommon contrarian insight into what really drives market dynamics.
To that end, my articles will center around stocks and their derivatives because that's where I have the most experience (over 20 years). I may occasionally comment on currencies, where I believe I have a sound academic knowledge, but less trading experience.I will always refer to a company by name or some abbreviation thereof. By contrast, I will refer to the stock a company issues by its ticker symbol. I think it can be important to differentiate between the two.
Graduate of Cornell University, 1958. Graduate Fellow, Univ of Chicago 1958-60.
Received Doctor of Laws degree from New York University School of Law, 1976. Have practiced litigation from 1976 until retirement in 2010. Have been an active stock investor since 1964,and active theatrical investor and producer since 2010.
Non-fiction editor of Playboy (1959-60). U.S.Army, chief of gun crew on atomic cannon (1960-61 + 7 yrs active reserves). Picture story editor of Argosy Magazine (1961-65) .Co-leader of the Trans-World Record Expedition (1965-66) and co-author of Who Needs A Road. Creative director and ad agency VP (1967-72). Legislative Director of Citizens Union and Common Cause, Albany, NY (1972-74). Practiced law, 1976-2009 with focus on civil litigation... . .
The Green River Intrinsic Value fund is a relatively concentrated, long/short equity strategy. The fund seeks long-term absolute returns investing in deeply mispriced securities which are identified through a careful process of methodical fundamental research and due diligence.
We strive to build highly disciplined, sensible client portfolios. Portfolios that are focused on investing in businesses with solid free cash flows and solid dividend payouts. We buy businesses, not stocks.
Tim is a Registered Investment Advisor.
Prufrock (pseudonym) is a small business owner, male, married, private individual invested in stocks primarily. He has been a Rambus investor for many years. Researching and writing about the company has become an avocation of his.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
Andrew Mickey is the Chief Investment Strategist of Q1 Publishing (http://www.q1publishing.com/). He has quickly emerged one of the world’s leading publishers of investment ideas and recommendations. Never one to get caught up in the herd, he has made his mark finding investment opportunities long before the rest of the pack catches on. Andrew, a contrarian to the core, has made extremely successful calls on coal, gold, silver, oil, potash, and technology stocks resulting in triple-digit gains for his readers. He is best known for urging investors to get out of ethanol stocks and buy fertilizer stocks during the height of the ethanol boom in July of 2006. His expertise and investing acumen his highly sought after. He currently sits on the advisory boards of two venture capital firms that have jointly controlled almost half a billion dollars in assets. Contact Andrew at amickey[at]q1publishing[dot]com.
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.
I have been a technology investor for over twenty-five years. My investing style includes a combination of Fundamental Analysis with Technical Analysis used for entry and exit points. I have followed several stocks involved in patent litigations including Rambus (RMBS), Interdigital (IDCC), Tessera (TSRA) and Star Scientific (STSI). I follow the actual trials, read the transcripts and the briefs and attempt to handicap the outcomes. I attend various hearings, trials, and oral arguments whenever possible, including appeals to the CAFC, and occasionally attend hearings/trials at various District Courts and the ITC. I have attended over 30 oral arguments at the CAFC and I have a good feel for the various judges.
Star Scientific (STSI) is my favorite stock for 2014. STSI has transformed themselves from a tobacco company to a Biopharma company in 2012 and 2013, and this year we will see the true value of the company now that scientific researchers are running the company. Star Scientific will also probably be changing their name in 2014, and may choose to become known as Rock Creek Pharmaceuticals (their division that produces Anatabloc). Although STSI has exited the tobacco manufacturing business (and settled with RJR for a paltry $5 Million), they still own key tobacco curing patents that have been validated by both the USPTO and the CAFC, and these patents don't expire until 2018. Star's new TSNA BDL patent (granted in 2012 by the USPTO) doesn't expire until 2030. I expect STSI (Rock Creek) to have a banner year in 2014 as the world starts to learn the miraculous ability of Anatabloc to treat a variety of auto immune diseases and other conditions associated with NF-kB inflammation (including MS, Rheumatoid Arthritis, Asthma, Crohn's, Parkinson's, Traumatic Brain Injury, Alzheimer's, and various types of cancer, etc). Rock Creek Pharmaceuticals should have more and more peer reviewed medical journal articles on the efficacy of Anatabloc coming out in 2014. I also expect that Rock Creek will file several drug applications (IND's) with the FDA in 2014. In addition, I expect Rock Creek Pharmaceuticals to team or partner with one or more Big Pharma companies for various human ailments as they pursue these IND's. For all these reasons, I expect Star Scientific to be at least a $10 stock before the end of the 2014, and possibly much higher than that.